Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) hits the market this week, and analysts are looking to its less frequent dosing schedule and lower cost to nab a substantial portion of the market from Roche AG's reigning VEGF inhibitors Lucentis (ranibizumab) and cheaper off-label cancer drug Avastin (bevacizumab) in wet age-related macular degeneration (AMD).